Articles

Update on the initial therapy of multiple myeloma

BJH - volume 5, issue 4, december 2014

M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, V. Delrieu MD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, A. Kentos MD, PhD, P. Mineur MD, F. Offner MD, PhD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, KL. Wu MD, PhD, C. Doyen MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD

Summary

With the introduction of immunomodulatory drugs and proteasome inhibitors, major improvements have been achieved in the treatment and prognosis of multiple myeloma. Different treatment combinations are now in use and innovative therapies are being developed. This rapidly changing therapeutic landscape calls for an update on the Belgian myeloma guidelines, published in 2010.1 Based on an extensive review of the recent literature, the myeloma study group of the Belgian Hematology Society has revised the consensus recommendations on myeloma care, to be used by haematologists as a reference for daily practice. When applicable, comments with regards to the Belgian reimbursement modalities are included. The full text with appendices can be downloaded from the Belgian Hematology Society website (www.bhs.be) and from the Belgium Journal of Hematology website (www.ariez.com).

(BELG J HEMATOL 2014;5(4):125–36)

Read more

O.1 ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): final results of LYSA H34 trial

BJH - volume 5, issue Abstract Book BHS, january 2014

M. André MD, PhD, B. De Prijck MD, A. Kentos MD, PhD, A. Van Hoof MD, PhD, C. Bonnet MD, PhD, A. Sonet MD, M. Maerevoet MD, E. Van den Neste MD, PhD, A. Bosly MD, PhD, N. Mounier

Read more

O.7 NOTCH1 c.7544–7545 delCt mutation identifies a subgroup of lymphocytic leukemia patients with poor outcome

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Franke , C. Herens , M. Jamar , N. Mongiovi , B. De Prijck MD, F. Lambert MD

Read more

P1.08 Hemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Sid MD, D. Dugauquier , B. De Prijck MD, C. Bonnet MD, PhD, Y. Beguin MD, PhD

Read more

P.07 Interim analysis of the randomized EORTC/ LYSA/FIL Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma

BJH - 2013, issue BHS Abstractbook, january 2013

P. André , E. Van den Neste MD, PhD, G. Verhoef MD, PhD, D. Bron MD, PhD, A. Van Hoof MD, PhD, P. Zachée MD, PhD, S. van Steenwegen , B. De Prijck MD, N. Straetmans MD, PhD, M. Maerevoet MD, D. Boulet , F. Offner MD, PhD, P. Pierre , V. Mathieux MD, PhD, P. Mineur MD, T. Connerotte MD, M. Federico , J. Raemaekers

Read more